ZeitlerPArslanianSFuJ, et al. ISPAD Clinical Practice Consensus Guidelines 2018: type 2 diabetes mellitus in youth. Pediatr Diabetes. 2018;19(suppl 27):28-46.
2.
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(suppl 1):S15-S33.
3.
HammanRFBellRADabeleaD, et al. The SEARCH for diabetes in youth study: rationale, findings, and future directions. Diabetes Care. 2014;37:3336-3344.
4.
Mayer-DavisEJLawrenceJMDabeleaD, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017;376:1419-1429.
5.
ConstantinoMIMolyneauxLLimacher-GislerF, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013;36:3863-3869.
6.
DyckRFJiangYOsgoodND.The long-term risks of end stage renal disease and mortality among First Nations and non-First Nations people with youth-onset diabetes. Can J Diabetes. 2014;38:237-243.
7.
WolfsdorfJIGlaserNAgusM, et al. ISPAD Clinical Practice Consensus Guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes. 2018;19(suppl 27):155-177.
8.
KlingensmithGJConnorCGRuedyKJ, et al. Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium. Pediatr Diabetes. 2016;17:266-273.
9.
ChaoLCVidmarAPGeorgiaS.Spike in diabetic ketoacidosis rates in pediatric type 2 diabetes during the COVID-19 pandemic. Diabetes Care. 2021;44:1451-1453.
10.
DruckerDJ.Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020;41:bnaa011.
11.
CzeislerMEMarynakKClarkeKEN, et al. Delay or avoidance of medical care because of COVID-19-related concerns—United States, June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1250-1257.
12.
GoyalMSinghPSinghKShekharSAgrawalNMisraS.The effect of the COVID-19 pandemic on maternal health due to delay in seeking health care: experience from a tertiary center. Int J Gynaecol Obstet. 2021;152:231-235.
13.
Mayer-DavisEJDabeleaDLawrenceJM.Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017;377:301.
14.
SamSEdelsteinSLArslanianSA, et al. Baseline predictors of glycemic worsening in youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2021;44:1938-1947.
15.
HannonTSEdelsteinSLArslanianSA, et al. Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. Pediatr Diabetes. 2020;21:1437-1446.
16.
RISE Consortium; RISE Consortium Investigators. Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on beta-cell function: comparison of responses in youth and adults. Diabetes. 2019;68:1670-1680.
17.
American Diabetes Association. 13. Children and adolescents: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(suppl 1):S180-S199.
18.
CefaluWTDawesDEGavlakG, et al. Insulin Access and Affordability Working Group: conclusions and recommendations. Diabetes Care. 2018;41:1299-1311.
19.
TillotsonCVBowdenSABoktorSW.Pediatric Type 2 Diabetes Mellitus. StatPearls; 2021.
20.
HaydenMR.An immediate and long-term complication of COVID-19 may be type 2 diabetes mellitus: the central role of beta-cell dysfunction, apoptosis and exploration of possible mechanisms. Cells. 2020;9:2475.
21.
MilletteKCualaJWangP, et al. SARS-CoV2 infects pancreatic beta cells in vivo and induces cellular and subcellular disruptions that reflect beta cell dysfunction. Res Sq. 2021. doi:10.21203/rs.3.rs-592374/v1
